A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): ...
Innovative approaches to drug screening—such as evaluation to identify the optimal solid state of a molecule and in-vitro characterization to establish the optimal solid state of a molecule and the ...
Bend, Ore.--Bend Research Inc., part of Capsugel's Dosage Form Solutions (DFS) business unit, announced today an investment of more than $20 million to expand commercial manufacturing for spray-dried ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback